SCHEMBL6981469

SCHEMBL6981469

CC(C)CC(NC(=O)OC(C)(C)C)C(=O)N1CCN(S(=O)(=O)N(C)C)CC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.48
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
HRH2 P25021 2/20 0.47
HRH1 P35367 2/20 0.47
KMT2A Q03164 5/20 0.46
MEN1 O00255 3/20 0.46
GAA P10253 2/20 0.46
CTSL P07711 2/20 0.44
CTSK P43235 2/20 0.44
CTSB P07858 1/20 0.44
CTSS P25774 1/20 0.44
CAPN1 P07384 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
MAPT P10636 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27475770 0.83 GAA (0.52) ALDH1A1LMNAKMT2AMEN1GAA
SCHEMBL1706174 0.81 MAPK1 (0.55) MAPK1ALDH1A1LMNAHRH2HRH1
SCHEMBL12535753 0.81 MAPK1 (0.55) MAPK1ALDH1A1LMNAHRH2HRH1
SCHEMBL1706172 0.81 MAPK1 (0.55) MAPK1ALDH1A1LMNAHRH2HRH1
SCHEMBL7352660 0.80 MAPK1 (0.54) MAPK1ALDH1A1LMNAHRH2HRH1
SCHEMBL6981849 0.79 KMT2A (0.57) MAPK1ALDH1A1LMNAHRH2HRH1
SCHEMBL13994325 0.79 MAPK1 (0.51) MAPK1ALDH1A1LMNAHRH2HRH1
SCHEMBL20120151 0.78 MAPK1 (0.53) MAPK1ALDH1A1LMNAHRH2HRH1
SCHEMBL22591021 0.78 CTSK (0.60) MAPK1ALDH1A1LMNAHRH2HRH1
SCHEMBL13994323 0.78 MAPK1 (0.53) MAPK1ALDH1A1LMNAHRH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
US-5935959-A CYSTEINE PROTEASE INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 1999-08-10 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
CN-1163145-A Inhibiting agent for vascular formation SENJI SEIYAKU K K (JP) 1997-10-29 CN disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed